Table 1.
Baseline characteristics
| Parameter | All Patients (n=241) | Intervention Arm (n=120) | Control Arm (n=121) |
|---|---|---|---|
| Recipient sex female | 77 (32%) | 40 (33%) | 37 (31%) |
| Recipient age | 54 (44–62) | 54 (44–63) | 53 (44–62) |
| Body mass index | 26.0 (22.6–29.2) | 25.7 (22.3–29.5) | 26.4 (22.8–29.0) |
| Renal disease | |||
| ADPKD | 48 (20%) | 20 (17%) | 28 (23%) |
| Diabetic nephropathy | 21 (9%) | 12 (10%) | 9 (7%) |
| Glomerulonephritis | 87 (36%) | 45 (38%) | 42 (35%) |
| Interstitial nephropathy | 12 (5%) | 7 (6%) | 5 (4%) |
| Vascular nephropathy | 25 (10%) | 15 (12%) | 10 (8%) |
| Other nephropathies | 34 (14%) | 15 (12%) | 19 (16%) |
| Unknown nephropathy | 14 (6%) | 6 (5%) | 8 (7%) |
| Renal replacement therapy | |||
| Preemptive transplantation | 36 (15%) | 18 (15%) | 18 (15%) |
| Dialysis vintage time, yr | 2.6 (1.2–4.3) | 2.8 (1.3–3.9) | 2.4 (0.9–4.7) |
| Deceased donor | 147 (61%) | 75 (63%) | 72 (60%) |
| Deceased donor details | |||
| Cold ischemia time, h | 10.0 (8.1–12.8) | 10.4 (8.0–13.1) | 10.0 (8.2–12.4) |
| DCD type | 44 (30%) | 23 (31%) | 21 (29%) |
| Donor age | 57 (48–65) | 58 (48–65) | 57 (48–64) |
| First transplant | 206 (85%) | 103 (86%) | 103 (85%) |
| Sensitizing events | |||
| Any | 111 (46%) | 56 (47%) | 55 (45%) |
| Prior kidney transplantation | 35 (15%) | 17 (14%) | 18 (15%) |
| Pregnancies | 59 (24%) | 28 (23%) | 31 (26%) |
| Blood transfusions | 61 (25%) | 31 (26%) | 30 (25%) |
| Current cPRA (A/B/C/DRB1/DRB345/DQB1/DPB1), % | 11 (0–58) | 21 (0–59) | 7 (0–56) |
| ABO incompatible | 20 (8%) | 10 (8%) | 10 (8%) |
| Pretransplant HLA-DSA | 30 (12%) | 16 (13%) | 14 (12%) |
| HLA-DSA characteristics | n=30 | n=16 | n=14 |
| Number | 2 (1–2) | 2 (1–3) | 2 (1–2) |
| Class (I/II/I+II) | 12/11/7 | 8/6/2 | 4/5/5 |
| Cumulative MFI | 1163 (500–2032) | 1163 (507–2799) | 1085 (500–1419) |
| HLA mismatches | |||
| A/B/C/DRB1/DRB345/DQB1/DPB1 | 8 (6–10) | 7 (6–10) | 8 (6–10) |
| A/B/C | 4 (3–5) | 4 (3–5) | 4 (3–5) |
| DRB1/DRB345/DQB1 | 3 (2–4) | 3 (2–4) | 3 (2–4) |
| Eplet load | |||
| Total eplet load | 60 (45–77) | 58 (45–77) | 65 (44–78) |
| Only antibody-verified eplets | 22 (16–28) | 22 (16–28) | 22 (17–30) |
| Total eplet load HLA-DQ | 11 (5–16) | 12 (4–16) | 11 (6–16) |
| Total eplet load HLA-DR | 14 (6–20) | 13 (6–22) | 14 (6–20) |
| CMV risk constellation | |||
| High risk (D+/R−) | 48 (20%) | 20 (17%) | 28 (23%) |
| Intermediate risk (R+) | 136 (56%) | 72 (60%) | 64 (53%) |
| Low risk (D−/R−) | 57 (24%) | 28 (23%) | 29 (24%) |
| Induction therapy | |||
| ATG | 40 (17%) | 20 (17%) | 20 (17%) |
| Basiliximab | 201 (83%) | 100 (83%) | 101 (83%) |
| Maintenance immunosuppression | |||
| Tac-MMF-P | 169 (70%) | 87 (73%) | 82 (68%) |
| Tac-MPS-P | 70 (29%) | 31 (26%) | 39 (32%) |
| Tac-Aza-P | 2 (1%) | 2 (1%) | — |
| Delayed graft function | 60 (25%) | 31 (26%) | 29 (24%) |
| Duration of hospitalization, d | 10 (8–15) | 10 (8–16) | 11 (8–15) |
Data are given as count (percentage) or median (interquartile range) as appropriate. ADPKD, autosomal polycystic kidney disease; DCD, donation after circulatory death; cPRA, calculated population-reactive antibodies; MFI, mean fluorescence intensity; HLA, human leucocyte antigen; HLA-DSA, donor-specific HLA antibodies; CMV, cytomegalovirus; ATG, anti–T-cell globulin; Tac, tacrolimus; MMF, mycophenolate mofetil; MPS, mycophenolate sodium; aza, azathioprine; P, prednisone.